Peri-Operative IABP Reduces In-Hospital Mortality for CAD Patients With Left Ventricular Dysfunction

0
0
0

Peri-Operative IABP Reduces In-Hospital Mortality for CAD Patients With Left Ventricular Dysfunction

Coronary artery disease (CAD) is the leading cause of left ventricular dysfunction—a condition where the heart’s main pumping chamber (left ventricle) doesn’t work as well as it should. For patients with CAD and reduced heart function, coronary artery bypass grafting (CABG)—a surgery to reroute blood around blocked arteries—carries higher risks, including death during hospitalization. But a 2019 study suggests a temporary heart support device could help: intra-aortic balloon pumping (IABP).

What Is IABP?

IABP is a minimally invasive tool that uses a small balloon inserted into the aorta (the body’s main artery). The balloon inflates during the heart’s resting phase (diastole) to boost blood flow to the coronary arteries (which feed the heart muscle) and deflates before the heart contracts (systole) to reduce the left ventricle’s workload. It’s designed to stabilize patients with weak hearts during high-risk procedures like CABG.

The Study: Does Peri-Operative IABP Save Lives?

Researchers at the General Hospital of People’s Liberation Army (Beijing, China) analyzed data from 612 patients who underwent CABG between 1995 and 2014. All patients had CAD and left ventricular dysfunction (ejection fraction, or EF, ≤ 50%—EF measures how much blood the left ventricle pumps out with each beat).

The goal? To see if using IABP peri-operatively (before, during, or after surgery) reduced in-hospital mortality (death during the hospital stay). Patients were split into two groups:

  • IABP group: 78 patients who received IABP support.
  • Non-IABP group: 534 patients who did not.

The team also looked at subgroups based on EF:

  • Severe dysfunction: EF ≤ 35% (132 patients).
  • Mild dysfunction: EF 36–50% (480 patients).

To ensure fair comparisons, they used logistic regression (to isolate IABP’s effect from other risk factors) and propensity score matching (PSM) (to pair IABP patients with non-IABP patients who had similar pre-op characteristics, like age, heart function, and surgical risk).

Key Results: IABP Is a Protective Tool—Even for Mild Dysfunction

The IABP group started with worse pre-op health:

  • Lower average EF (36.5% vs. 41.2% in the non-IABP group).
  • Higher predicted mortality (5.67% vs. 2.08% via EuroSCOREII, a tool to estimate surgical risk).

But when it came to actual in-hospital mortality, the groups were nearly identical: 2.56% (IABP) vs. 3.00% (non-IABP). That’s remarkable—because the IABP group was sicker, their mortality should have been higher. Instead, IABP leveled the playing field.

The Big Win: IABP Is a “Protective Factor”

Logistic regression revealed that IABP use was independently linked to a lower risk of in-hospital death. Even after adjusting for other risks (like recent heart attacks, emergency surgery, or post-op arrhythmias), IABP reduced mortality risk.

Subgroup Analysis: Benefit Extends to Mild Dysfunction

Prior guidelines (e.g., ACC/AHA 2011) recommended IABP only for severe dysfunction (EF < 30%). But this study found:

  • Severe dysfunction (EF ≤ 35%): IABP cut mortality risk.
  • Mild dysfunction (EF 36–50%): IABP also reduced mortality—and this group makes up most clinical cases.

After PSM (matching 64 IABP patients to 64 non-IABP patients), the results were even starker:

  • IABP group: 0% in-hospital mortality.
  • Non-IABP group: 6.25% in-hospital mortality.

That’s a clear signal: proactive IABP use works for patients across the dysfunction spectrum.

Why Does IABP Help?

IABP’s dual action is key:

  1. Boosts coronary blood flow: Inflation during diastole pushes more blood into the coronary arteries, delivering oxygen to the heart muscle—critical for patients with CAD.
  2. Reduces left ventricular load: Deflation during systole lowers the resistance the left ventricle faces when pumping, easing strain on a weakened heart.

For patients with CAD and left ventricular dysfunction, this means less risk of further heart damage, more stable blood flow, and a higher chance of surviving surgery.

What This Means for Patients and Doctors

The study challenges old assumptions: IABP isn’t just for the “sickest” patients. It’s a valuable tool for any CAD patient with left ventricular dysfunction undergoing CABG—including those with milder EF levels (36–50%).

For doctors: Proactive IABP use could save lives. For patients: This study offers hope that even with a weakened heart, surgery can be safer.

Limitations to Consider

Like all research, this study has caveats:

  • Retrospective design: It looks back at past data, so there’s a risk of selection bias (e.g., doctors might have used IABP on sicker patients).
  • Single-center: Results need confirmation from larger, multi-center trials.
  • Small IABP group: Only 78 patients received IABP—future studies with more participants could strengthen the findings.

The Bottom Line

For patients with CAD and left ventricular dysfunction, peri-operative IABP is a game-changer. It reduces in-hospital mortality, stabilizes blood flow, and works for both severe and mild heart function impairment. As the medical community continues to refine surgical care for high-risk patients, this study adds strong evidence for using IABP proactively.

Original study by Xiao-Yi He and Chang-Qing Gao, Department of Cardiovascular Surgery, General Hospital of People’s Liberation Army, Beijing, China. Published in the Chinese Medical Journal (2019). DOI: doi.org/10.1097/CM9.0000000000000178

Was this helpful?

0 / 0